secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-275395
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q3 net loss $21.7M, cash $165.5M; Phase 3 melanoma trial fully enrolled
--------------------------------------------------------------------------------

- Net loss $21.7M in Q3 2023 vs $15.7M Q3 2022; R&D expenses $17.7M (up from $10.0M) driven by Phase 3 trial.
- Cash and equivalents $165.5M at Sept 30, 2023, including $75M private placement; cash runway into Q4 2025.
- Completed enrollment of 380 patients in pivotal Phase 3 (IO102-IO103 + pembrolizumab) for advanced melanoma; interim ORR expected Q3 2024, PFS H2 2025.
- Appointed Helen Collins, MD to board; she serves as Chair of R&D Committee and brings extensive oncology drug development experience.
- Presented encouraging preliminary Phase 2 data at WCLC and ESMO; three non-clinical posters at SITC 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/0001193125-23-275395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/d893930d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-275395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer